Pocket guide: biologics in upper and lower airways in adults

W J Fokkens; V Backer; V J Lund; P J Barnes; M Bernal-Sprekelsen; L Bjermer; E de Corso; D M Conti; M E Cornet; Z Diamant; R Djukanovic; M Gaga; P Gevaert; J K Han; C Hopkins; G Joos; B N Landis; S Lau; S E Lee; J Mullol; A T Peters; G K Scadding; S Schneider; B Senior; I D Pavord; S Quirce; D Ryan; M E Wechsler; P W Hellings

doi:10.4193/Rhin24.510

Pocket guide: biologics in upper and lower airways in adults

W J Fokkens^*, V Backer, V J Lund, P J Barnes, M Bernal-Sprekelsen, L Bjermer, E de Corso, D M Conti, M E Cornet, Z Diamant, R Djukanovic, M Gaga, P Gevaert, J K Han, C Hopkins, G Joos, B N Landis, S Lau, S E Lee, J MullolA T Peters, G K Scadding, S Schneider, B Senior, I D Pavord, S Quirce, D Ryan, M E Wechsler, P W Hellings

^*Corresponding author af dette arbejde

Afdeling for Øre-, Næse-, Halskirurgi og Audiologi HOC

3 Citationer (Scopus)

Abstract

The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.

Originalsprog	Engelsk
Tidsskrift	Rhinology
Vol/bind	63
Udgave nummer	2
Sider (fra-til)	242-244
Antal sider	3
ISSN	0300-0729
DOI	https://doi.org/10.4193/Rhin24.510
Status	Udgivet - 1 apr. 2025

Adgang til dokumentet

10.4193/Rhin24.510

Andre filer og links

Link to publication in Scopus

Citationsformater

Fokkens, W. J., Backer, V., Lund, V. J., Barnes, P. J., Bernal-Sprekelsen, M., Bjermer, L., de Corso, E., Conti, D. M., Cornet, M. E., Diamant, Z., Djukanovic, R., Gaga, M., Gevaert, P., Han, J. K., Hopkins, C., Joos, G., Landis, B. N., Lau, S., Lee, S. E., ... Hellings, P. W. (2025). Pocket guide: biologics in upper and lower airways in adults. Rhinology, 63(2), 242-244. https://doi.org/10.4193/Rhin24.510

Fokkens, WJ, Backer, V, Lund, VJ, Barnes, PJ, Bernal-Sprekelsen, M, Bjermer, L, de Corso, E, Conti, DM, Cornet, ME, Diamant, Z, Djukanovic, R, Gaga, M, Gevaert, P, Han, JK, Hopkins, C, Joos, G, Landis, BN, Lau, S, Lee, SE, Mullol, J, Peters, AT, Scadding, GK, Schneider, S, Senior, B, Pavord, ID, Quirce, S, Ryan, D, Wechsler, ME & Hellings, PW 2025, 'Pocket guide: biologics in upper and lower airways in adults', Rhinology, bind 63, nr. 2, s. 242-244. https://doi.org/10.4193/Rhin24.510

@article{c4087f2a1a624df5ae0eda3b21227571,

title = "Pocket guide: biologics in upper and lower airways in adults",

abstract = "The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.",

keywords = "Adult, Asthma/drug therapy, Biological Products/therapeutic use, Humans, Pulmonary Disease, Chronic Obstructive/drug therapy, Rhinitis/drug therapy, Sinusitis/drug therapy, Biological Products/standards",

author = "Fokkens, {W J} and V Backer and Lund, {V J} and Barnes, {P J} and M Bernal-Sprekelsen and L Bjermer and {de Corso}, E and Conti, {D M} and Cornet, {M E} and Z Diamant and R Djukanovic and M Gaga and P Gevaert and Han, {J K} and C Hopkins and G Joos and Landis, {B N} and S Lau and Lee, {S E} and J Mullol and Peters, {A T} and Scadding, {G K} and S Schneider and B Senior and Pavord, {I D} and S Quirce and D Ryan and Wechsler, {M E} and Hellings, {P W}",

year = "2025",

month = apr,

day = "1",

doi = "10.4193/Rhin24.510",

language = "English",

volume = "63",

pages = "242--244",

journal = "Rhinology",

issn = "0300-0729",

publisher = "University Hospital Utrecht",

number = "2",

}

TY - JOUR

T1 - Pocket guide

T2 - biologics in upper and lower airways in adults

AU - Fokkens, W J

AU - Backer, V

AU - Lund, V J

AU - Barnes, P J

AU - Bernal-Sprekelsen, M

AU - Bjermer, L

AU - de Corso, E

AU - Conti, D M

AU - Cornet, M E

AU - Diamant, Z

AU - Djukanovic, R

AU - Gaga, M

AU - Gevaert, P

AU - Han, J K

AU - Hopkins, C

AU - Joos, G

AU - Landis, B N

AU - Lau, S

AU - Lee, S E

AU - Mullol, J

AU - Peters, A T

AU - Scadding, G K

AU - Schneider, S

AU - Senior, B

AU - Pavord, I D

AU - Quirce, S

AU - Ryan, D

AU - Wechsler, M E

AU - Hellings, P W

PY - 2025/4/1

Y1 - 2025/4/1

N2 - The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.

AB - The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.

KW - Adult

KW - Asthma/drug therapy

KW - Biological Products/therapeutic use

KW - Humans

KW - Pulmonary Disease, Chronic Obstructive/drug therapy

KW - Rhinitis/drug therapy

KW - Sinusitis/drug therapy

KW - Biological Products/standards

UR - http://www.scopus.com/inward/record.url?scp=105002857022&partnerID=8YFLogxK

U2 - 10.4193/Rhin24.510

DO - 10.4193/Rhin24.510

M3 - Review

C2 - 40042485

SN - 0300-0729

VL - 63

SP - 242

EP - 244

JO - Rhinology

JF - Rhinology

IS - 2

ER -

Pocket guide: biologics in upper and lower airways in adults

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater